Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 14/20 | 0.38 |
| ▸ | CASR | P41180 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5580686 | 1.00 | ADRB2 (0.38) | ADRB2CASRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13807616 | 0.93 | ADRB2 (0.37) | ADRB2CASRELANE | |
| SCHEMBL2962085 | 0.91 | ADRB2 (0.48) | ADRB2CASR | |
| SCHEMBL2962080 | 0.91 | ADRB2 (0.48) | ADRB2CASR | |
| SCHEMBL6530358 | 0.90 | ADRB2 (0.39) | ADRB2CASRRXRBELANETBXA2R | |
| SCHEMBL6530365 | 0.90 | ADRB2 (0.39) | ADRB2CASRRXRBELANETBXA2R | |
| SCHEMBL3627411 | 0.89 | RAB9A (0.36) | ADRB2SLC6A2SLC6A3ELANE | |
| SCHEMBL3625629 | 0.89 | ADRB2 (0.36) | ADRB2CASRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3627413 | 0.89 | RAB9A (0.36) | ADRB2SLC6A2SLC6A3ELANE | |
| SCHEMBL3625631 | 0.89 | ADRB2 (0.36) | ADRB2CASRSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241810-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | PFIZER LIMITED (GB) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | FH, FAH, HRH4 | ADRB2 751/4885CASR 4499/4885SLC6A2 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.